Neprilysin (NEP) is a type II membrane metalloendopeptidase composed of ∼750 residues with an active site containing a zinc-binding motif (HEXXH) at the extracellular carboxyl terminal domain.Neprilysin has the ability to break down both the oligomeric and monomeric forms of the A peptide. The main A-peptide-degrading enzyme in the brain is called neprilysin, and both aging and Alzheimer's disease (AD) cause neprilysin to become inactive and down-regulated.
Neutral endopeptidase neprilysin increases the bioavailability of substance P, bradykinin, and natriuretic peptides, which has natriuretic, vasodilatory, and anti-proliferative effects.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4540 | Sacubitril hemicalcium | 1369773-39-6 | Sacubitril hemicalcium (also known as AHU377; AHU-377; Entresto), thehemicalcium salt of Sacubitril which is a component of the heart failure medicine LCZ696 (sacubitril/valsartan), is a novel and potentNEP (neutral endopeptidase 24.11)inhibitor with anIC50of 5 nM. |
|
V4542 | Sacubitrilat (LBQ-657) | 149709-44-4 | Sacubitrilat (formerly known as LBQ-657; LBQ657) is the activated form of Sacubitril (AHU-377; AHU-377; Entresto), which is a novel and potentNEP (neutral endopeptidase 24.11)inhibitor used in combination with valsartan (LCZ696) for treating heart failure. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
